We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

SEBIA

Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App





Sebia Displays Automated, High Throughput Capillary Electrophoresis (CE) Instruments at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 12 Apr 2022

Sebia (Lisses, France) displayed its capillary electrophoresis (CE) instruments designed to provide complete automation, with fast protein separation at high resolution at EUROMEDLAB 2022. More...

CE allows a rapid and accurate signature-based measurement for major chronic diseases diagnosis and monitoring and is routinely used in clinical laboratories for screening of serum and other fluids for protein abnormalities. At EUROMEDLAB 2022, Sebia demonstrated CAPILLARYS 3 TERA MC configuration that allows the combination of one to three CAPILLARYS 3 TERA instruments to a Sebia loader, with a loading capacity of 528 samples in one row. This high volume workcell provides three hours autonomy on HbA1c, and hemoglobin testing, and more than two hours on proteins, processing up to 528 samples in one go. The system can be fed continuously with additional racks, and the reagent management system allows ad-hoc reagent addition at any time, without interruption.

Sebia also highlighted its CAPILLARYS 3 DBS high throughput solution for newborn hemoglobin disorders screening. CE is also a proven technology for hemoglobin disorders screening and provides high quality results. Sebia CAPILLARYS 3 DBS is the latest generation of instrument dedicated to newborn hemoglobin screening, offering a smooth workflow and excellent analytical features. The CAPILLARYS 3 DBS instrument is an automated, multitasking capillary electrophoresis instrument using 12 capillaries for multiple simultaneous hands-free electrophoretic separations at high throughput.

The CAPILLARYS 3 DBS enables the analysis of samples from microplate wells and provides fully automated electrophoresis separation, from the dried blood spots on filter paper (Guthrie card) through to the final electrophoretic pattern: sample identification, sample dilution, sample incubation, capillary washing, sample injection into the capillaries, migration, detection, processing of the results, and transfer over the computer interface. This instrument is an interesting alternative to commonly used technology such as IEF and HPLC for all the laboratories involved in newborn hemoglobin screening, bringing seamless sample traceability, high quality results, and high throughput while offering a reduced hands-on time.

Related Links:
Sebia 


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.